Verbände-Stellungnahme zum EMA-„Advice on the designation of antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans – in relation to implementing measures under Article 37(5) of Regulation (EU) 2019/6 on veterinary medicinal products“

Report an error

Summary

AI-generated

This summary is written by a language model reading the source document. It is not the publisher's words and is not a substitute for the original.

Learn more about AI enrichment

A coalition of NGOs criticizes the EMA's recommendations for reserving antibiotics for human use, claiming the list excludes all antibiotics currently approved for veterinary use and thus fails to combat antimicrobial resistance in livestock.

Key insights

AI-generated

These insights are written by a language model reading the source document. They are not the publisher's words and are not a substitute for the original.

Learn more about AI enrichment
  • The EMA's list of antibiotics to be reserved for human medicine contains no substances that are currently approved for veterinary use, meaning it does not contribute to preventing the spread of antibiotic-resistant bacteria in livestock farming.
  • The EMA's classification of substances under 'Criterion C' (indispensable in veterinary medicine) is described as completely opaque and contradictory to World Health Organization (WHO) assessments, specifically regarding Highest Priority Critically Important Antimicrobials (HP CIA) such as third and fourth generation cephalosporins, polymyxins, macrolides, and (fluoro-)quinolones.
  • Evidence suggests that the use of critical antibiotics like Colistin can be significantly reduced through non-pharmaceutical interventions; for example, Colistin sales in Estonia fell by 92.5% between 2013 and 2019 following the introduction of an E. coli vaccine for pigs.

Cite the original document

APA
Lührs, I., Benning, R., Tsilimekis, K., & Striezel, A. (2022). Verbände-Stellungnahme zum EMA-„Advice on the designation of antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans – in relation to implementing measures under Article 37(5) of Regulation (EU) 2019/6 on veterinary medicinal products“. Germanwatch. https://www.germanwatch.org/de/85114
Chicago
Lührs, Imke, Reinhild Benning, Konstantinos Tsilimekis, and Andreas Striezel. Verbände-Stellungnahme zum EMA-„Advice on the designation of antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans – in relation to implementing measures under Article 37(5) of Regulation (EU) 2019/6 on veterinary medicinal products“. Germanwatch, 2022. https://www.germanwatch.org/de/85114.
Wikipedia
{{cite press release |last1=Lührs |first1=Imke |last2=Benning |first2=Reinhild |last3=Tsilimekis |first3=Konstantinos |last4=Striezel |first4=Andreas |title=Verbände-Stellungnahme zum EMA-„Advice on the designation of antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans – in relation to implementing measures under Article 37(5) of Regulation (EU) 2019/6 on veterinary medicinal products“ |publisher=Germanwatch |date=14 March 2022 |url=https://www.germanwatch.org/de/85114 |access-date=5 November 2026 |via=Climate Insights Directory (document gerwat-000017)}}
BibTeX
@misc{lhrs2022verbndestellungnahme, author = {Lührs, Imke and Benning, Reinhild and Tsilimekis, Konstantinos and Striezel, Andreas}, title = {{Verbände-Stellungnahme zum EMA-„Advice on the designation of antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans – in relation to implementing measures under Article 37(5) of Regulation (EU) 2019/6 on veterinary medicinal products“}}, publisher = {Germanwatch}, year = {2022}, month = mar, url = {https://www.germanwatch.org/de/85114}, urldate = {2026-11-05}, note = {Indexed by Climate Insights Directory, document gerwat-000017} }

Full text

Collected · Record updated